Myocardial Perfusion Quantification With SPECT Using Multi-Pinhole Collimator Compared to Photon-Counting Coronary CTA
Launched by SEMMELWEIS UNIVERSITY · Oct 31, 2024
Trial Information
Current as of June 27, 2025
Recruiting
Keywords
ClinConnect Summary
This clinical trial is investigating how well two different imaging techniques can detect problems related to coronary artery disease, which is a condition that affects the blood vessels supplying the heart. The study aims to compare the results from a special type of heart scan called myocardial perfusion SPECT (MPI SPECT) with those from a coronary computed tomography angiography (coronary CTA) scan. Researchers hope that by measuring blood flow in the heart during these scans, they can improve how doctors assess heart health and better identify patients at risk for heart issues.
The trial is looking for 50 participants who are suspected of having coronary artery disease and have been referred for either a coronary CTA or MPI SPECT scan by their doctor. Eligible participants should be able to give informed consent and must not have certain health conditions, such as severe valve issues or active cancer treatment. Those who join the study will undergo both types of scans, which will help researchers gather important information to enhance heart disease diagnosis and treatment. If you or a loved one is interested in participating, it’s a chance to contribute to research that could lead to better heart care for many patients in the future.
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • suspected coronary artery disease
- • referred to coronary CTA or SPECT MPI by the patient's physician
- • agrees to the other imaging modality that was not indicated by their physician (coronary CTA or SPECT MPI)
- • suitable for informed consent
- Exclusion Criteria:
- • moderate or severe aortic valve stenosis
- • atrial fibrillation
- • pregnancy or breastfeeding
- • history of coronary artery bypass graft implantation
- • history of stent implantation
- • chronic renal failure (eGFR \< 30 ml/m2)
- • active oncological treatment
- • congenital heart disease
- • left or right bundle branch block
About Semmelweis University
Semmelweis University, located in Budapest, Hungary, is a prestigious institution renowned for its commitment to advancing medical education, research, and healthcare innovation. As a prominent clinical trial sponsor, the university leverages its extensive expertise in various medical fields to conduct rigorous clinical studies aimed at improving patient outcomes and enhancing therapeutic strategies. With a focus on ethical standards and scientific excellence, Semmelweis University collaborates with a network of healthcare professionals and researchers to translate groundbreaking discoveries into practical applications, ultimately contributing to the global advancement of medical science.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Budapest, , Hungary
Patients applied
Trial Officials
Pál Maurovich-Horvat, Prof. Dr.
Principal Investigator
Semmelweis University Medical Imaging Centre
Tamás Györke, MD
Study Chair
Semmelweis University Department of Nuclear Medicine
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported